Comparative Pharmacology
Head-to-head clinical analysis: ASENDIN versus DOXEPIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASENDIN versus DOXEPIN HYDROCHLORIDE.
ASENDIN vs DOXEPIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxapine, a dibenzoxazepine tricyclic antidepressant, primarily inhibits the reuptake of norepinephrine and serotonin. Its metabolite, 7-hydroxyamoxapine, exhibits dopamine D2 receptor antagonism, contributing to its antipsychotic effects.
Doxepin is a tricyclic antidepressant (TCA) that inhibits the reuptake of serotonin and norepinephrine, thereby increasing their concentrations in the synaptic cleft. It also exhibits potent histamine H1 receptor antagonism, leading to antihistaminic effects, and has anticholinergic, alpha-adrenergic blocking, and anti-serotonergic properties.
50 mg orally three times daily, increased gradually to 100-200 mg/day in divided doses. Max 300 mg/day.
25-150 mg orally at bedtime; initially 25 mg, may increase gradually to 150 mg. For minor depression: 25-50 mg orally at bedtime.
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours. Clinical context: Steady-state is reached within 5-7 days; the half-life supports once-daily dosing in most patients.
Terminal elimination half-life: 8-24 hours (mean 15 hours). Steady-state achieved in 3-5 days. Active metabolite nordoxepin has half-life of 31-50 hours.
Renal (approximately 50% as unchanged drug and metabolites), biliary/fecal (30-40%), with the remainder as other metabolites; <10% excreted unchanged in urine.
Primarily renal (50-60% as metabolites, <5% unchanged). Biliary/fecal: approximately 20-30%.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant